公开(公告)号：US20180177778A1

公开(公告)日：2018-06-28

申请号：US15738762

申请日：2016-06-28

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Tolga Baykal ,  Barry M. Bernstein ,  Scott c. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino X Rodrigues Jr. ,  Regis A. Vilchez

IPC: A61K31/497 ,  A61P31/14 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/7056

CPC classification number: A61K31/497 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/7056 ,  A61P31/14 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.